XSHE300871
Market cap242mUSD
Dec 25, Last price
10.33CNY
1D
-0.83%
1Q
25.76%
IPO
-79.48%
Name
Wuhan Hvsen Biotechnology Co Ltd
Chart & Performance
P/E
101.58
P/S
1.67
EPS
0.10
Div Yield, %
2.87%
Shrs. gr., 5y
6.64%
Rev. gr., 5y
19.31%
Revenues
1.02b
-0.31%
Net income
17m
-68.16%
CFO
93m
-3.89%
Dividend
May 29, 20240.27 CNY/sh
Earnings
May 15, 2025
Profile
Hvsen Biotechnology Co., Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. Its products include tylvalosin raw materials, various tylvalosin preparations, florfenicol preparations, and other macrolides products. The company produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. is based in Wuhan, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 1,019,759 -0.31% | 1,022,901 2.68% | 996,217 28.14% | |||||
Cost of revenue | 903,787 | 897,195 | 836,866 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 115,971 | 125,705 | 159,351 | |||||
NOPBT Margin | 11.37% | 12.29% | 16.00% | |||||
Operating Taxes | (4,339) | 4,003 | 17,967 | |||||
Tax Rate | 3.18% | 11.27% | ||||||
NOPAT | 120,311 | 121,702 | 141,384 | |||||
Net income | 16,781 -68.16% | 52,706 -60.33% | 132,866 -11.52% | |||||
Dividends | (48,969) | (54,910) | (45,308) | |||||
Dividend yield | 2.04% | 1.63% | 0.96% | |||||
Proceeds from repurchase of equity | (3,310) | (4,628) | ||||||
BB yield | 0.14% | 0.10% | ||||||
| Debt | ||||||||
Debt current | 240,587 | 220,085 | 106,417 | |||||
Long-term debt | 601,657 | 570,360 | 580,981 | |||||
Deferred revenue | 62,339 | 48,889 | 42,080 | |||||
Other long-term liabilities | 845 | 1,690 | 2,895 | |||||
Net debt | 244,377 | (7,510) | (411,052) | |||||
| Cash flow | ||||||||
Cash from operating activities | 92,919 | 96,680 | 155,718 | |||||
CAPEX | (184,312) | |||||||
Cash from investing activities | (100,304) | |||||||
Cash from financing activities | 710,088 | |||||||
FCF | (83,528) | (265,999) | (231,458) | |||||
| Balance | ||||||||
Cash | 597,867 | 785,722 | 1,098,450 | |||||
Long term investments | 4 | 12,234 | 1 | |||||
Excess cash | 546,879 | 746,811 | 1,048,639 | |||||
Stockholders' equity | 507,830 | 664,350 | 738,192 | |||||
Invested Capital | 1,906,879 | 1,705,184 | 1,601,751 | |||||
ROIC | 6.66% | 7.36% | 11.15% | |||||
ROCE | 4.76% | 5.26% | 6.81% | |||||
| EV | ||||||||
Common stock shares outstanding | 165,982 | 165,431 | 166,082 | |||||
Price | 14.46 -29.12% | 20.40 -28.37% | 28.48 6.99% | |||||
Market cap | 2,400,106 -28.88% | 3,374,803 -28.65% | 4,730,013 7.19% | |||||
EV | 2,644,483 | 3,367,292 | 4,318,961 | |||||
EBITDA | 236,361 | 188,276 | 187,892 | |||||
EV/EBITDA | 11.19 | 17.88 | 22.99 | |||||
Interest | 28,216 | 18,376 | 2,872 | |||||
Interest/NOPBT | 24.33% | 14.62% | 1.80% | |||||